Theranica’s Nerivio® REN wearable represents a major leap forward in migraine treatment by offering a clinically validated, drug-free alternative that leverages remote electrical neuromodulation (REN) technology. Uniquely designed for both acute and preventive care, the FDA-cleared device is the first of its kind to serve patients as young as 8 years old. The REN wearable is applied to the upper arm and activated via smartphone, delivering personalized electrical stimulation that triggers conditioned pain modulation mechanisms, providing targeted relief without pharmaceuticals or invasive procedures.
Recent real-world studies presented at the 2025 American Headache Society (AHS) Annual Meeting reaffirm Nerivio’s long-term reliability and broad clinical relevance. One study demonstrated consistent pain relief and symptom control over three years of use, with no evidence of tolerance or diminished response—an important finding in a condition marked by chronicity and variability. Another study showed that Nerivio is equally effective in patients with and without migraine aura, highlighting its utility across the full spectrum of migraine presentations and validating its use in a broad patient population.
As more patients and providers seek sustainable, side effect-free treatment options, Theranica’s REN wearable stands out as a scalable and safe solution that supports both quality of life and long-term adherence. By eliminating the risks of medication overuse and offering consistent performance over time, Nerivio not only fills a critical gap in migraine care but also sets a new standard for non-invasive neuromodulation therapies. These findings further strengthen Theranica’s leadership in wearable therapeutics and its mission to transform how migraine is managed across the globe.
MedTech Spectrum's Summary
Long-Term Efficacy Without Tolerance: Theranica’s real-world studies show that the Nerivio® REN wearable provides consistent migraine relief over three years of use, with no signs of treatment fatigue or reduced effectiveness—addressing a major gap in sustainable migraine care.
Broad Applicability Across Migraine Types: The device demonstrated comparable effectiveness in treating migraines with and without aura, reinforcing its reliability across diverse patient populations and symptom profiles.
Drug-Free, Durable Relief: As a non-invasive, medication-free solution for both acute and preventive migraine treatment, Nerivio offers a safe, side-effect-free alternative that improves patient adherence and supports long-term quality of life.
